| Date | Title | Description |
| 20.02.2026 | Buy this best-in-class GLP-1 leader as competition heats up, says Barclays | - |
| 10.01.2026 | 2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market | In 2026, new obesity pills will push the booming GLP-1 market into its next chapter.
Pills may serve as a more convenient — and in certain cases cheaper — alternative to today’s blockbuster injections that could attract entirely new patient... |
| 01.01.2026 | 2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit | - |
| 15.12.2025 | Here Monday’s biggest analyst calls: Nvidia, Tesla, Apple, Viking, Hershey, Marriott, Dollar General & more | - |
| 11.12.2025 | Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly | Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its “Metabolic Frontier 2030” strategy.
The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment... |
| 09.12.2025 | Stocks making the biggest moves premarket: Home Depot, Ares, Viking, CVS, Nvidia & more | - |
| 04.11.2025 |
Cramer’s Lightning Round: ‘I’m going to take a pass’ on Zoom | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Viking Therapeutics: ”...Own Eli Lilly.”
Al... |
| 04.09.2025 |
Cramer’s Lightning Round: No to Viking Therapeutics | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Palantir: “Palantir I still think is going ... |
| 24.08.2025 | Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors | Some analysts say Eli Lilly’s daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors.
In the trial, orforglipron caused weight loss that m... |
| 19.08.2025 | Stocks making the biggest moves midday: Home Depot, Intel, Viking Therapeutics, Nvidia and more | - |
| 19.08.2025 | Viking Therapeutics shares fall 40% on disappointing obesity pill trial data | Shares of Viking Therapeutics fell 40% on Tuesday after the company released midstage trial data on its obesity pill that disappointed investors.
While the weight loss caused by Viking’s pill was roughly comparable to that of other oral dru... |
| 07.08.2025 | Eli Lilly shares drop after obesity pill shows modest late-stage trial results | Eli Lilly said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial.
They bring Eli Lilly’s pill, orforglipron, one step closer to potential... |
| 17.04.2025 | Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14% | Eli Lilly said its daily obesity pill met the company’s goals in the first of several closely watched late-stage trials.
The pill helped Type 2 diabetes patients lower their blood sugar and body weight and showed safety on par with popular ... |
| 17.04.2025 | Lilly weight-loss pill works as well as Ozempic, shares surge | Lilly weight-loss pill works as well as Ozempic, shares surge
By Deena Beasley and Manas MishraApril 17, 20254:02 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The logo of Lilly is seen on a w... |
| 25.03.2025 | The Weight of Expectations: A Look at the Obesity Drug Market's Rollercoaster Ride | The obesity drug market is a battleground, where hopes soar and plummet with each trial result. Recent developments from Novo Nordisk and Eli Lilly illustrate this volatile landscape. Both companies are vying for dominance in a sector proje... |
| 24.03.2025 | Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer | Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year.
The trial results are among the pharmaceutical industry’s most critical of the year, as... |
| 18.10.2024 | The Microbiome Revolution: Holobiome's $9 Million Leap Forward | In the world of health and wellness, the gut is the new frontier. Holobiome, a microbiome platform company, has just secured $9 million in a Seed funding round. This investment is not just a financial boost; it’s a signal that the microbiom... |
| 18.10.2024 | Consumer groups ask FTC to block Novo Holdings-Catalent deal | Boards, Policy & RegulationMergers & Acquisitions
Regulatory Oversight
Corporate Counsel
Health
Consumer groups ask FTC to block Novo Holdings-Catalent deal
By Jody Godoy and Maggie FickOctober 17, 20249:55 PM UTCUpdated ago
Text
Sm... |
| 10.09.2024 | Дешевле, эффективнее и без уколов. Новый «Оземпик» на подходе | Кажется, что человечество стало еще на шаг ближе к исполнению «ленивых желаний». Никаких тренировок, никакой диеты – закинул таблетку и почти безвредно похудел. И если препарат Оземпик стоил дорого и вводился иглой, то теперь на рынке новый... |
| 04.04.2024 | The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months | Markets The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
William Edwards
2024-04-04T14:09:13Z
Share icon An curved arrow pointing ri... |
| 07.03.2024 | Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss | An experimental Novo Nordisk obesity pill led to weight loss of 13.1% in a clinical trial, topping results posted in studies of the company’s approved injectable medication Wegovy. It’s early days and more testing is needed, but the prelimi... |
| 18.07.2023 | The two-horse race to make blockbuster obesity drugs | The push to develop blockbuster weight loss drugs has turned into a two-horse race between Novo Nordisk and Eli Lilly, and the stakes are rising.
Driving the news: Lilly's planned $1.9 billion acquisition of privately held Versanis Bio, ann... |
| 10.02.2022 | Viking Therapeutics : Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update - Form 8-K | Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today
• Data From Three Clinical Programs Expected in the Next 12-18 Months
• Enrollment... |
| 03.11.2021 | Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K | Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today
• Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Proceeding
• Phase 1b Proof-... |
| 24.06.2021 | Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD | |
| 17.06.2021 | Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214 | |
| 06.01.2021 | Viking Therapeutics Announces Senior Management Team Appointments | |
| 05.01.2021 | Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference | |
| 22.09.2016 | The next Sage? Shkreli partner Ligand puts together another sweet startup package deal for Seelos | San Diego-based Ligand Pharmaceuticals $LGND has created a startup licensing package for a still incipient drug developer, complete with a built-in loan and some modest upfront terms for a pipeline that includes a Phase... |
| 25.08.2016 |
Viking Therapeutics Raises $12.5M In PIPE
| San Diego-based biopharmaceutiacls developer Viking Therapeutics says it has raised $12.5M in a common stock purchase agreement, from Aspire Capital Fund. The company, which is publicly traded on the NASDAQ as VKTX, said the initial purchas... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 22.05.2014 | In California biotech deal, startup Viking Therapeutics snags 5 programs, $2.5M | Its lead candidate is an oral inhibitor of the enzyme FBPase, which plays an important role in how the body synthesizes glucose. According to Viking, the small-molecule drug has demonstrated safety and tolerability in early clinical trials ... |
| - | Viking Therapeutics stock jumps 120% after positive weight loss drug trial results | Shares of Viking Therapeutics soared after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial.
Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight ... |
| - | Dow dips 200 points in choppy trading ahead of presidential election: Live updates | Stocks struggled to hold their ground on Monday as investors geared up for the U.S. presidential election and a potential Federal Reserve rate cut later this week.
The Dow Jones Industrial Average slumped 217 points, or about 0.5%. The S&am... |
| - | In California biotech deal, startup Viking Therapeutics snags 5 programs, $2.5M | A San Diego biotech startup focused on treating metabolic and endocrine disorders has picked up a portfolio of drug candidates and a $2.5 million investment from Ligand Pharmaceuticals (NASDAQ:LGND).
Viking Therapeutics said it’s licensed f... |
| - | The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space | Drugmakers have been scrambling to join a two-horse race to make highly sought after weight loss drugs.
There may still be room for lesser-known competitors like the privately held Boehringer Ingelheim, and smaller public companies such as ... |
